Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598377 | 0.87 | NPSR1 (0.43) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL4822241 | 0.87 | NPSR1 (0.39) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL21826086 | 0.84 | CYP3A4 (0.38) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL27915505 | 0.80 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL15428502 | 0.78 | NPSR1 (0.33) | NPSR1 | |
| SCHEMBL25349015 | 0.77 | LMNA (0.43) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL3665233 | 0.74 | LMNA (0.52) | LMNASMN1; SMN2FFAR3NPSR1 | |
| SCHEMBL19537161 | 0.70 | FFAR3 (0.38) | LMNASMN1; SMN2FFAR3NPSR1 | |
| Hydrochloric Acid SCHEMBL18725618 | 0.69 | DGAT1 (0.38) | LMNANPSR1 | |
| SCHEMBL19537486 | 0.69 | NPSR1 (0.36) | LMNASMN1; SMN2FFAR3NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4522615-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066356-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4479388-A1 | ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4298097-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230391764-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023220238-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116897155-A | Benzothiazolyl bicyclo [1.1.1] pentane derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-4247811-A1 | BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC | 2019-09-19 | — | — | US | disclosed |
| US-20190031641-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| EP-3194382-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044447-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-8633182-B2 | Indanyloxyphenylcyclopropanecarboxylic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633182-B2 | Indanyloxyphenylcyclopropanecarboxylic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| EP-2530078-A1 | THIAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| WO-2010136778-A1 | DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136778-A1 | DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | LMNA 1783/4885SMN1; SMN2 2125/4885FFAR3 3034/4885 |
| US-20250066356-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | LMNA 2763/4885SMN1; SMN2 766/4885FFAR3 3422/4885 |
| US-20170291889-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | LMNA 4353/4885SMN1; SMN2 2723/4885FFAR3 2713/4885 |
| US-20190284168-A1 | PYRAZOLE DERIVATIES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | LMNA 4316/4885SMN1; SMN2 2559/4885FFAR3 2673/4885 |
| US-20230391764-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, SLC10A1, BCL2A1 | LMNA 1906/4885SMN1; SMN2 3235/4885FFAR3 1323/4885 |
| US-20190031641-A1 | PYRAZOLE DERIVATIVES AS SGC STIMULATORS | PTGIS, GMPS, NOS3 | LMNA 4353/4885SMN1; SMN2 2723/4885FFAR3 2713/4885 |
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | SCN1B, SCN2B, SCN11A | LMNA 2547/4885SMN1; SMN2 2425/4885FFAR3 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.